MS4A1 and non-Hodgkin lymphoma: First preclinical evaluations were performed with 227Th-p-benzyl-DOTA-rituximab (or 227Th-rituximab) for the targeting of CD20 receptors expressed at the surface of B cells in Non-Hodgkin lymphoma (NHL) or leukemia.